

**CURRICULUM VITAE
HELEN HASKELL HOBBS**

Birth Date, Place: May 5, 1952, Boston, Massachusetts

Address: Department of Molecular Genetics
University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Boulevard
Dallas, Texas 75390-9046
Telephone: (214) 648-6724
Fax: (214) 648-7539
e-mail: Helen.Hobbs@UTSouthwestern.edu

Marital Status: Married (Dennis Keith Stone, M.D.)

Children: Langdon Gundry Stone, May 7, 1984
Hunter Hobbs Stone, December 30, 1985

EDUCATION & TRAINING:

1970-1971 University of Pennsylvania, Philadelphia, PA
1971-1974 B.A., Human Biology, Stanford University, Palo Alto, CA
1975-1979 M.D., Case Western Reserve University School of Medicine, Cleveland, OH
1979-1980 Intern, Internal Medicine, Columbia Presbyterian Medical Center, New York City, NY
1980-1982 Resident, Internal Medicine, University of Texas Southwestern Medical Center (UT Southwestern), Dallas, TX
1982-1983 Chief Resident, Department of Internal Medicine, UT Southwestern
1983-1987 Postdoctoral Fellowship, Department of Molecular Genetics & Subspecialty Training in Endocrinology and Metabolism, UT Southwestern

POSITIONS:

1987-1991 Assistant Professor, Departments of Internal Medicine and Molecular Genetics, and Chief, Division of Medical Genetics, UT Southwestern
1991-1995 Associate Professor, Departments of Internal Medicine and Molecular Genetics, and Chief, Division of Medical Genetics, UT Southwestern
1995- Professor, Departments of Internal Medicine and Molecular Genetics, and Chief, Division of Medical Genetics, UT Southwestern
2000- Director, McDermott Center for Human Growth and Development, UT Southwestern
2002- Investigator, Howard Hughes Medical Institute

ELECTED MEMBERSHIPS:

Alpha Omega Alpha, 1979
American Society of Clinical Investigation, 1991
Institute of Medicine, National Academy of Science, 2004
Association of American Physicians, 1997
American Academy of Arts and Sciences, 2006
National Academy of Sciences, 2007

HONORS AND AWARDS:

Alfred S. Maschke Award for Excellence in the Art & Practice of Medicine, Case Western Reserve University School of Medicine, 1979
Syntex Scholar, 1987-1990
Established Investigator, American Heart Association, 1990 -1995
Bristol Myers Squibb Metabolism Freedom to Discover Research Grant, 2002-2007
Honorary Degree in Medicine, University of Ferrara, Ferrara, Italy, 2003
Heinrich Wieland Prize, 2005
Clinical Research Prize, American Heart Association, 2005
Distinguished Alumnus Award, Case Western Reserve University School of Medicine, 2006
Distinguished Scientist Award, American Heart Association, 2007
Glorney-Raisbeck Award, New York Academy of Medicine, 2007
International Society of Atherosclerosis Prize, 2012 (inaugural award)
Pasarow Foundation Award in Cardiovascular Research, 2013
Breakthrough Prize in Life Sciences, 2015
Pearl Meister Greengard Prize, Rockefeller University, 2015
Passano Award (with Jonathan Cohen), 2016

NAMED LECTURESHIPS:

Pincoffs Lecture, U. of Maryland School of Medicine, Baltimore, MD: December, 2000
DeWitt S. Goodman Lectureship in Nutrition and Preventive Medicine, College of Physicians & Surgeons of Columbia U., New York, NY: December, 2002
Howard Eder Memorial Lecture, Albert Einstein College of Medicine, New York, NY: April, 2004
Gill Lecture, Cardiovascular Series, U. of Kentucky, Lexington, KY: January, 2005
Heinrich Wieland Prize Lecture, Ludwig Maximillian U., Munich, GR: November, 2005
Glorney Raisbeck Award, New York Academy of Medicine, New York, NY: February, 2008
Richard Havel Lecture, 2008 Duell Conference, San Diego, CA: March, 2008
Fred Kern Lecturer, Aspen Lipid Conference, Aspen, CO: August, 2008
Irving Page Lecture, Cleveland Clinic, Cleveland, OH: November, 2008
Wu Distinguished Visiting Professor Lecture, College of Physicians & Surgeons of Columbia U., New York, NY: November, 2008
Mission Bay Lecture, University of California, San Francisco, CA: April, 2009
Edward Rubenstein Lecturer, Stanford U., Stanford, CA: January, 2009
Maclyn McCarty Lecture, Rockefeller Institute, New York City, NY: February, 2009
Paul Dudley White Lecture, Massachusetts General Hospital, Harvard U., Boston, MA: May, 2009
Shirley Johnson Memorial Plenary Lecture, International Society of Thrombosis & Hemostasis, Boston, MA: July, 2009
Arthur C. Guyton Distinguished Lectureship Award, Association of Chairs of Dept. of Physiology, Tucson, AZ: December, 2009
Karl Landsteiner Memorial Award and Lectureship, Austrian Academy of Science, Vienna, AT: April, 2010
Astute Clinician Lecture, National Institute of Health, Washington, DC: November, 2010
AHA Distinguished Scientist Lecture, Annual Meeting of American Heart Association, Chicago, IL: November, 2010

Dr. Charles S. Leiber Lecture, American Gastroenterological Association, Chicago, IL: May, 2011
William Sydney Thayer and Susan Read Thayer Lectureship in Clinical Medicine, Johns Hopkins University, Baltimore, MD: September, 2011
Oliver Smithies Distinguished Lecturer, U. of North Carolina, Chapel Hill, NC: November, 2011
Ruijsch Lecture, Academic Medical Center, Amsterdam, Netherlands: January, 2013
Distinguished Biomedical Scholars Lecture, University of Iowa, Iowa City, IO: February, 2013
Louis F. Bishop Lecturer, American College of Cardiology, San Francisco, CA: March 9, 2013
Trefethen Seminar, University of California, San Francisco, CA: April 30, 2013
Visscher Symposium Keynote Lecture, University of Minnesota, MN: May 22, 2014
Burton E. Sobel Lecture, Washington U., St. Louis, MO: November 7, 2014
George Lyman Duff Memorial Lecture, American Heart Association: November 17, 2014
JLR Lectureship Award, Keynote Lecture, Keystone Meeting, Sante Fe, NM: January 28, 2015
Benning Society Lecture, U. of Utah: March 10, 2015
Harvey Society Lecture, Rockefeller U., New York City, NY: March 19, 2015
Levi J. Hammond Distinguished Memorial Lecture, U. of Penn., Philadelphia, PA: May 12, 2015
Cartwright Lecture & Prize, Columbia U., New York, NY: July 23, 2015
Bernadine Healy Lecture, Cleveland Clinic, Cleveland, OH: November 12th, 2015

BOARD CERTIFICATION:

American Board of Internal Medicine, 1983
 Subspecialty Certification, Endocrinology and Metabolism, 1986

ORGANIZATIONS (Current):

American Society of Human Genetics
 American Society for Biochemistry and Molecular Biology
 Arteriosclerosis, Thrombosis and Vascular Disease Council of the American Heart Association

EDITORIAL BOARDS (Current):

Consulting Editor, Journal of Clinical Investigation, 1993-1996, 1997-present
 Cell Metabolism, 2004-present
 Board of Reviewing Editors, eLife, 2012-present

CORPORATE BOARDS (Current)

Pfizer, Inc., 2011-present

COMMITTEE MEMBERSHIP (National & International):

Cardiovascular Disease Advisory Committee, NHLBI, 1990-1994
 American Society for Clinical Investigation Council, 1992-1995
 Vice-President, 1996-1997
 Scientific Advisory Board of Stanley J. Sarnoff Endowment for Cardiovascular Science, Advisory Board, 1998-2002
 President 2001-2002
 Editor Selection Committee for Journal of Clinical Investigation, 2000, 2006, 2011
 Mammalian Genetics Study Section, National Institute of Health, 2000
 Culpeper Medical Scholar Advisory Board, 2004-2008
 Life Sciences Institute Advisory Board, U. of Michigan, 2003-present
 Doris Duke Charitable Foundation's Medical Research Scientific Advisory Council, 2004-2009

Chair, 2009-present
 Singapore Biomedical Sciences International Advisory Committee, 2006-2012
 National Heart, Lung and Blood Advisory Council, National Institute of Health, 2006-2009
 Advisory Council to the NIH Director, Working Group on Peer Review, 2007-2008
 National Advisory Council of the Stanford School of Medicine, 2010-2012
 Scientific Committee of the Louis-Jeantet Foundation, Geneva, Switzerland, 2010-present
 Advisory Committee to the NIH Director: National Center for the Advancing Translational Sciences Working Group, 2010-2011
 Richard Lounsbery Award Selection Committee, 2011
 Advisory Committee to the Director, National Institute of Health, 2012- 2015
 Jessie Stevenson Kovalenko Medal Selection Committee, National Academy of Sciences, 2012, 2015
 Clinical Temporary Nominating Group, National Academy of Sciences, 2013-present
 Advisory Committee to Director: Chair, Laboratory-based Physician Scientist Workforce, 2013
 Board of Directors, American Society of Human Genetics, 2012-2015
 Scientific Advisory Committee, LeDucq Foundation, 2013-present
 Gruber Genetics Prize Selection Committee, 2014-present
 Class IV CMC, National Academy of Sciences, 2014-present
 Rosalind Franklin Award Selection Committee, 2015

PATENTS:

Methods for Modulation of Lipid Uptake, U.S. Patent 5,925,333, issued 7/20/99
Drug Screen for Identifying an Agent That Modulates Low Density Lipoprotein Receptor Adaptor-Ligand Binding, US Patent 6,465,196, issued 10/15/02
ABCG8 Vectors, Host Cells, & Method of Making Antibodies, US Patent 6,821,750, issued 11/23/04
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease, US Pat No. 7,883,851, issued Feb 08, 2011
Variations in PNPLA3 Associated with Hepatic Steatosis, filed 2009

PUBLICATIONS:

1. **Hobbs H.H.**, Lehrman M.A., Yamamoto T., Russell D.W. (1985) Polymorphism and evolution of Alu sequences in the human low density lipoprotein receptor gene. Proc. Natl. Acad. Sci. USA 82:7651-7655.
2. **Hobbs H.H.**, Brown M.S., Goldstein J.L., Russell D.W. (1986) Deletion of exon encoding cysteine-rich repeat of low density lipoprotein receptor alters its binding specificity in a subject with familial hypercholesterolemia. J. Biol. Chem. 261:13114-13120.
3. Russell D.W., **Hobbs H.H.**, Lehrman M.A. (1986) The LDL receptor gene: A DNA in transition. In Lerman, L. (ed.) *Current Communications in Molecular Biology: Application of DNA Probes*, Cold Spring Harbor Laboratory, New York, pp. 31-36.
4. Russell D.W., Lehrman M.A., Sudhof T.C., Yamamoto T., Davis C.G., **Hobbs H.H.**, Brown M.S., Goldstein J.L. (1986) The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein. Cold Spring Harb. Symp. Quant. Biol. 51: 811-819.

5. **Hobbs H.H.**, Esser V., Russell D.W. (1987) AwaII polymorphism in human LDL receptor gene. Nucleic Acids Res. 15: 379.
6. Leitersdorf E., **Hobbs H.H.** (1987) Human LDL receptor gene: Two ApaLI RFLPs. Nucleic Acids Res. 15:2782.
7. **Hobbs H.H.**, Brown M.S., Russell D.W., Davignon J., Goldstein J.L. (1987) Deletion in LDL receptor gene occurs in majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:734-737.
8. Leitersdorf E., **Hobbs H.H.** (1988) Human LDL receptor gene: HincII polymorphism detected by gene amplification. Nucleic Acids Res. 16:7215.
9. **Hobbs H.H.**, Leitersdorf E., Goldstein J.L., Brown M.S., Russell D.W. (1988) Multiple mutations in familial hypercholesterolemia: Evidence for 13 alleles, including four deletions. J. Clin. Invest. 81:909-917.
10. Leitersdorf E., **Hobbs H.H.**, Fourie A.H., Jacobs M., van der Westhuyzen D., Coetzee G.A. (1988) Deletion in the first cysteine-rich repeat of low density lipoprotein receptor impairs its transport but not lipoprotein binding in fibroblasts from a subject with familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 85:7912-7916.
11. Leitersdorf E., Chakravarti A., **Hobbs H.H.** (1989) Polymorphic DNA haplotypes at the LDL receptor locus. Am. J. Hum. Genet. 44:409-421.
12. Russell D.W., Esser V., **Hobbs H.H.** (1989) The molecular basis of familial hypercholesterolemia. Arteriosclerosis 9:8-13.
13. **Hobbs H.H.**, Leitersdorf E., Leffert C., Cryer D., Brown M.S., Goldstein J.L. (1989) Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective LDL receptors. J. Clin. Invest. 84:656-664.
14. Leitersdorf E., Van der Westhuyzen D. R., Coetzee G.A., **Hobbs H.H.** (1989) Two common LDL receptor gene mutations cause familial hypercholesterolemia in Afrikaners. J. Clin. Invest. 84:954-961.
15. Leitersdorf E., Tobin E.J., Davignon J., **Hobbs H.H.** (1990) Common low density lipoprotein receptor mutations in the French Canadian population. J. Clin. Invest. 85:1014-1023.
16. Zuliani G., **Hobbs H.H.** (1990) A high frequency of length polymorphisms in repeated sequences adjacent to Alu sequences. Am. J. Hum. Genet. 46:963-969.
17. Zuliani G., **Hobbs H.H.** (1990) EcoNI polymorphism in the human cholesteryl ester transfer protein (CETP) gene. Nucleic Acids Res. 18:2834.
18. Zuliani G., **Hobbs H.H.** (1990) Tetranucleotide repeat polymorphism in the apolipoprotein B gene. Nucleic Acids Res. 18:4299.
19. **Hobbs H.H.**, Russell D.W., Brown M.S., Goldstein J.L. (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. In Cambell, A., Baker, B.S., Jones, E.W. (eds.) Annu. Rev. Genet. 24:133-170.
20. Zuliani G., **Hobbs H.H.** (1990) Tetranucleotide repeat polymorphism in the apolipoprotein C-III gene. Nucleic Acids Res. 18:4299.
21. Zuliani G., **Hobbs H.H.** (1990) Dinucleotide repeat polymorphism at the 3' end of the LDL receptor gene. Nucleic Acids Res. 18:4300.

22. Zuliani G., **Hobbs H.H.** (1990) Tetranucleotide repeat polymorphism in the LPL. Nucleic Acids Res. 18:4958.
23. Vega G.L., **Hobbs H.H.**, Grundy S.M. (1991) Low density lipoprotein kinetics in a family having defective low density lipoprotein receptors in which hypercholesterolemia is suppressed. Arteriosclerosis 11:578-585.
24. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., **Hobbs H.H.** (1991) Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87:2153-2161.
25. Boerwinkle E., Leffert C.C., Lin J., Lackner C., Chiesa G., **Hobbs H.H.** (1992) Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma Lipoprotein(a) concentration. J. Clin. Invest. 90:52-60.
26. Cohen J.C., Cali J.J., Jelinek D.F., Mehrabian M., Sparkes R.S., Lusis A.J., Russell D.W., **Hobbs H.H.** (1992) Cloning of the human cholesterol 7 α -hydroxylase gene (CYP7) and localization to chromosome 8q11-q12. Genomics 14:153-161.
27. Chiesa G., **Hobbs H.H.**, Koschinsky M.L., Lawn R.M., Maika S.D., Hammer R.E. (1992) Reconstitution of lipoprotein(a) by infusion of human LDL into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267:24369-24374.
28. **Hobbs H.H.**, Brown M.S., Goldstein J.L. (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:445-466.
29. Cohen J., Chiesa G., **Hobbs H.H.** (1993) Sequence polymorphisms in the apolipoprotein (a) gene: evidence for dissociation between apo(a) size and plasma lipoprotein(a) levels. J. Clin. Invest. 91:1630-1636.
30. Lackner C., Cohen J.C., **Hobbs H.H.** (1993) Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum. Mol. Genet. 2:933-940.
31. Moliterno D.J., Lange R.A., Meidell R.S., Willard J.E., Leffert C.C., Gerard R.D., Boerwinkle E., **Hobbs H.H.**, Hillis L.D. (1993) Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 88:935-940.
32. Chiesa G., Johnson D.F., Yao Z., Innerarity T.L., Mahley W., Young S.G., Hammer R.H., **Hobbs H.H.** (1993) Expression of human apolipoprotein B100 in transgenic mice. Editing of human apoB100 mRNA. J. Biol. Chem. 268:23747-23750.
33. Linton M.F., Farese R.V., Jr., Chiesa G., Grass D.S., Chin P., Hammer R.E., **Hobbs H.H.**, Young S.G. (1993) Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92:3029-3037.
34. Zuliani G., **Hobbs H.H.** (1994) Tetranucleotide length polymorphism 5' of the alpha-2 macroglobulin (A2MR)/LDL receptor related protein (LRP) gene. Hum. Mol. Genet. 3: 215.
35. **Hobbs H.H.**, Chiesa G., Gaw A., Lawn R., Maika S.D., Koschinsky M., Hammer R. (1994) Apo(a) expression in transgenic mice. In Fitzgerald, G.A., Jennings, L.K., Patrono, C. (eds.) Ann. N. Y. Acad. Sci. 714:231-236.
36. Jokinen V., Sakai J., Yamamoto T., **Hobbs H.H.** (1994) CGG triple repeat polymorphism in VLDL receptor (VLDL-R) gene. Hum. Mol. Genet. 3:521.
37. Gaw A., Boerwinkle E., Cohen J.C., **Hobbs H.H.** (1994) Comparative analysis of the apo(a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus. J. Clin. Invest. 93:2526-2534.

38. Rudel L.L., Newton R., Hamilton R. Jr., Deckelbaum R.J., **Hobbs H.H.** (1994) 1993 Aspen Cholesterol/Bile Acid Conference: Diet and gene interactions in cholesterol metabolism. J. Lipid Res. 35:1122-1128.
39. McCormick S.P., Linton M.F., **Hobbs H.H.**, Taylor S., Curtis L.K., Young S. (1994) Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein J. Biol. Chem. 269: 24284-24289.
40. Jokinen E.V., Landschulz K.T., Wyne K.L., Ho Y.K., Frykman P.K., **Hobbs H.H.** (1994) Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle. J. Biol. Chem. 269:26411-26418.
41. **Hobbs H.H.**, Scott J. (1994) Genetics and molecular biology of lipid metabolism. Curr. Opin. Lipidol. 5:77-80.
42. Gaw A., **Hobbs H.H.** (1994) Molecular genetics of lipoprotein(a): new pieces to the puzzle. (1994) Curr. Opin. Lipidol. 5:149-155.
43. Hua X., Wu J., Goldstein J.L., Brown M.S., **Hobbs H.H.** (1995) Structure of human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 25:667-673.
44. Mooser V., Mancini F.P., Boop S., Pethö-Schramm A.P., Guerra R., Boerwinkle E., Mueller H.J., **Hobbs H.H.** (1995) Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum. Mol. Genet. 4:173-181.
45. Moliterno D.J., Jokinen E.V., Miserez A.R., Lange R.A., Willard J.E., Boerwinkle E., Hillis L.D., **Hobbs H.H.** (1995) No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler. Thromb. Vasc. Biol. 15:850-855.
46. Scott J., **Hobbs H.H.** (1995) Genetics and molecular biology of lipid metabolism. Curr. Opin. Lipidol. 6:67-69.
47. Mancini F.P., Mooser V., Guerra R., **Hobbs H.H.** (1995) Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum. Mol. Genet. 4:1535-1542.
48. Mancini F.P., Newland D.L., Mooser V., Murata J., Marcovina S., Young S.G., Hammer R.E., Sanan D.A., **Hobbs H.H.** (1995) Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler. Thromb. Vasc. Biol. 15:1911-1916.
49. Cohen J.C., Gaw A., Barnes R.I., Landschulz K.T., **Hobbs H.H.** (1996) Genetic factors that contribute to interindividual variations in plasma low density lipoprotein-cholesterol levels. Ciba Found. Symp. 197:194-206.
50. Mooser V., Seabra M.C., Abedin M., Landschulz K.T., Marcovina S., **Hobbs H.H.** (1996) Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J. Clin. Invest. 97:858-864.
51. Wyne K.L., Pathak K., Seabra M.C., **Hobbs H.H.** (1996) Expression of the VLDL receptor in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16:407-415.
52. Acton S., Rigotti A., Landschulz K.T., Xu S., **Hobbs H.H.**, Krieger M. (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520.

53. Marcovina S.M., **Hobbs H.H.**, Albers J.J. (1996) Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basic a standardized isoform nomenclature. Clin. Chem. 42:436-439.
54. Landschulz K.T., Pathak R.K., Rigotti A., Krieger M., **Hobbs H.H.** (1996) Regulation of scavenger receptor, Class B, Type 1, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J. Clin. Invest. 98:984-995.
55. Mooser V., Marcovina S.M., White A.L., **Hobbs H.H.** (1996) Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98:2414-2424.
56. Miserez A.R., Cao G., Probst L., **Hobbs H.H.** (1997) Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2). Genomics 40:31-40.
57. Mooser V., Scheer D., Marcovina S.M., Wang J., Guerra R., Cohen J.C., **Hobbs H.H.** (1997) The apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African-Americans. Am. J. Hum. Genet. 61:401-417.
58. Cao G., Garcia C.K., Wyne K.L., Schultz R.A., Parker K.L., **Hobbs H.H.** (1997) Structure and localization of the human gene encoding SR-BI/CLA1. Evidence for transcriptional control by steroidogenic factor 1. J. Biol. Chem. 272:33068-33076.
59. Mooser V., Marcovina S.M., Wang J., **Hobbs H.H.** (1997) High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clin. Genet. 52:387-392.
60. Mooser V., **Hobbs H.H.** (1997) Lipoprotein(a) and growth hormone: is the puzzle solved? Eur. J. Endocrin. 137:450-452.
61. Sanan D.A., Newland D.L., Tao R., Marcovina S., Wang J., Mooser V., Hammer R.E., **Hobbs H.H.** (1998) Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc. Natl. Acad. Sci. USA 95:4544-4549.
62. Spady D.K., Woollett L.A., Meidell R.S., **Hobbs H.H.** (1998) Kinetic characteristics and regulation of HDL cholesteryl ester and apoprotein transport in the Apo A-I^{-/-} mouse. J. Lipid Res. 39:1483-1492.
63. Stangl H., Cao G., Wyne K.L., **Hobbs H.H.** (1998) Scavenger receptor, class B, type I-dependent stimulation of cholesteryl esterification by high density lipoproteins, low density lipoproteins and nonlipoprotein cholesterol. J. Biol. Chem. 273:31002-31008.
64. Acquati F., Hammer R., Ercoli B., Mooser V., Tao R., Röncke V., Michalich A., Chiesa G., Taramelli R., **Hobbs H.H.**, Müller H-J. (1999) Transgenic mice expressing a human apolipoprotein(a) allele. J. Lipid Res. 40:994-1006.
65. **Hobbs H.H.**, Rader D.J. (1999) ABC1: connecting yellow tonsils, neuropathy and very low HDL. J. Clin. Invest. 104:1015-1017.
66. Ruixian T., Acquati F., Marcovina S.M., **Hobbs H.H.** (1999) Human growth hormone increases apo(a) expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 19:2439-2447.
67. Spady D.K., Kearney D.M., **Hobbs H.H.** (1999) Polyunsaturated fatty acids upregulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J. Lipid Res. 40:1384-1394.

68. **Hobbs H.H.**, White A.L. (1999) Lp(a): intrigues and insights. Curr. Opin. Lipidol. 10:225-236.
69. Cao G., Zhao L., Stangl H., Hasegawa T., Richardson J.A., Parker K.L., **Hobbs H.H.** (1999) Developmental and hormonal regulation of murine scavenger receptor, class B, type 1. Mol. Endocrinol. 13:1460-1473.
70. Stangl H., Hyatt M., **Hobbs H.H.** (1999) Transport of lipids from high and low density lipoproteins via scavenger receptor-BI. J. Biol. Chem. 274:32692-32698.
71. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schwartz J., Kwiterovich P., Shan B., Barnes R., **Hobbs H.H.** (2000) Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-1775.
72. Wang J., Boedeker J., **Hobbs H.H.**, White A.L. (2001) Determinants of human apolipoprotein(a) secretion from mouse hepatocyte cultures. J. Lipid Res. 42:60-69.
73. Garcia C.K., Mues G., Liao Y., Hyatt T., Patil N., Cohen J.C., **Hobbs H.H.** (2001) Sequence diversity in genes of lipid metabolism. Genome Res. 11:1043-1052.
74. Garcia C.K., Wilund K., Arca M., Zuliani G., Felin R., Maioli M., Calandra S., Bertolini S., Cossu F., Grishin N., Barnes R., Cohen J.C., **Hobbs H.H.** (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394-1398.
75. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., Marcel Y.L., Anderson R.G.W., Mendelsohn M.E., **Hobbs H.H.**, Shaul P.W. (2001) High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853-857.
76. Hubacek J.A., Berge K.E., Cohen J.C., **Hobbs H.H.** (2001) Mutations in ATP-cassette binding proteins (ABCG5) and (ABCG8) causing sitosterolemia. Hum. Mutat. 18:359-360.
77. Berge K.E., von Bergmann K., Lutjohann D., Guerra R., Grundy S.M., **Hobbs H.H.**, Cohen J.C. (2002) Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J. Lipid Res. 43:486-494.
78. Arca M., Zuliani G., Wilund K., Campagna F., Fellin R., Bertolini S., Calandra S., Ricci G., Glorioso N., Maioli M., Pintus P., Carru C., Cossu F., Cohen J.C., **Hobbs H.H.** (2002) Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 359:841-847.
79. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., **Hobbs H.H.**, Mangelsdorf D.J. (2002) Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277:18793-18800.
80. Graf G.A., Li W.P., Gerard R.D., Gelissen I., White A., Cohen J.C., **Hobbs H.H.** (2002) Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J. Clin. Invest. 110:659-669.
81. Yu L., Li-Hawkins J., Hammer R.E., Berge K.E., Horton J.D., Cohen J.C., **Hobbs H.H.** (2002) Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110:671-680.
82. He G., Gupta S., Yi M., Michaely P., **Hobbs H.H.**, Cohen J.C. (2002) ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin and AP-2. J. Biol. Chem. 277: 44044-44049.

83. Wilund K.R., Yi M., Campagna F., Arca M., Zuliani G., Fellin R., Ho Y.K., Garcia J.V., **Hobbs H.H.**, Cohen J.C. (2002) Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum. Mol. Genet. 11:3019-3030.
84. Yu L., Hammer R.E., Li-Hawkins J., von Bergmann K., Lutjohann D., Cohen J.C., **Hobbs H.H.** (2002) Disruption of Abcg5 and Abcg8 in mice reveals crucial role in biliary secretion. Proc. Natl. Acad. Sci. USA 99:16237-16242.
85. **Hobbs H.H.**, Graf G.A., Yu L., Wilund K.R., Cohen J.C. (2002) Genetic defenses against hypercholesterolemia. Cold Spring Harb. Symp. Quant. Biol. 67:499-505.
86. Cohen J.C., Kimmel M., Polanski A., **Hobbs H.H.** (2003) Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr. Opin. Lipidol. 14:121-127.
87. Yu L., York J., von Bergmann K., Lutjohann D., Cohen J.C., **Hobbs H.H.** (2003) Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 278:15565-15570.
88. Jones C., Hammer R.E., Li W.P., Cohen J.C., **Hobbs H.H.**, Herz J. (2003) Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J. Biol. Chem. 278:29024-29030.
89. Rader D.J., Cohen J., **Hobbs H.H.** (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111:1795-1803.
90. Graf G.A., Yu L., Li W.P., Gerard R., Tuma P.L., Cohen J.C., **Hobbs H.H.** (2003) ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278:48275-48282.
91. Yu L., von Bergmann K., Lutjohann D., **Hobbs H.H.**, Cohen J.C. (2004) Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 45:301-307.
92. Victor R.G., Haley R.W., Willett D., Peshock R.M., Vaeth P.C., Leonard D., Basit M., Cooper R.S., Iannacchione V.G., Visscher W., Staab J., **Hobbs H.H.** (2004) The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am. J. Cardiol. 93:1473-1480.
93. Graf G.A., Cohen J.C., **Hobbs H.H.** (2004) Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking. J. Biol. Chem. 279:24881-24888.
94. Wilund K.R., Yu L., Xu F., **Hobbs H.H.**, Cohen J.C. (2004) High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr^{-/-} mice. J. Lipid Res. 45:1429-1436.
95. Michaely P., Li W., Anderson R.G., Cohen J.C., **Hobbs H.H.** (2004) The modular adaptor protein ARH is required for LDL binding and internalization, but not for low density lipoproteins receptor clustering in coated pits. J. Biol. Chem. 279:34023-34031.
96. Cohen J.C., Kiss R.S., Pertsemlidis A., Marcel Y.L., McPherson R., **Hobbs H.H.** (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869-872.
97. Jain T., Peshock R., McGuire D.K., Willett D., Yu Z., Vega G.L., Guerra R., **Hobbs H.H.**, Grundy S.M. and the Dallas Heart Study Investigators (2004) African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J. Am. Coll. Cardiol. 44:1011-1017.
98. Yang C., Yu L., Li W., Xu F., Cohen J.C., **Hobbs H.H.** (2004) Disruption of cholesterol homeostasis by plant sterols. J. Clin. Invest. 114:813-822.

99. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., **Hobbs H.H.** (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395.
100. Wilund K.R., Yu L., Xu F., Vega G.L., Grundy S.M., Cohen J.C., **Hobbs H.H.** (2004) No association between plasma levels of plant sterol levels and atherosclerosis in mice and men. Arterioscler. Thromb. Vasc. Biol. 24:2326-2332.
101. Szczepaniak L.S., Nuremberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., **Hobbs H.H.**, Dobbins R.L. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288:E462-468.
102. Yu L., Gupta S., Xu F., Liverman A.D., Moschetta A., Mangelsdorf D.J., Repa J.J., **Hobbs H.H.**, Cohen J.C. (2005) Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 280:8742-8747.
103. Cohen J.C., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., **Hobbs H.H.** (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161-165.
104. Guerra R., Yu Z., Marcovina S., Peshock R., Cohen J.C., **Hobbs H.H.** (2005) Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 111:1471-1479.
105. Langheim S., Yu L., von Bergmann K., Lutjohann D., Xu F., **Hobbs H.H.**, Cohen J.C. (2005) ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 46:1732-1738.
106. Yu L., von Bergmann K., Lutjohann D., **Hobbs H.H.**, Cohen J.C. (2005) Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 46:1739-1744.
107. Moschetta A., Xu F., Hagey L.R., van Berge-Henegouwen G.P., van Erpecum K.J., Brouwers J.F., Cohen J.C., Bierman M., **Hobbs H.H.**, Steinbach J.H., Hofmann A.F. (2005) A phylogenetic survey of biliary lipids in vertebrates. J. Lipid Res. 46:2221-2232.
108. Xu F., Rychnovsky S.D., Belani J.D., **Hobbs H.H.**, Cohen J.C., Rawson R.B. (2005) Dual roles for cholesterol in mammalian cells. Proc. Natl. Acad. Sci. USA 102:14551-14556.
109. Garuti R., Jones C., Li W.P., Michaely P., Hertz J., Gerard R.D., Cohen J.C., **Hobbs H.H.** (2005) The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J. Biol. Chem. 280:40996-41004.
110. Yi M., Horton J.D., Cohen J.C., **Hobbs H.H.**, Stephens R.M. (2006) WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 7:7-30.
111. Zhang D.W., Graf G.A., Gerard R.D., Cohen J.C., **Hobbs H.H.** (2006) Functional asymmetry of nucleotide-binding domains in ABCG5 and ABCG8. J. Biol. Chem. 281: 4507-4516.
112. Cohen J.C., Pertsemlidis A., Fahmi S., Esmail S., Vega G.L., Grundy S.M., **Hobbs H.H.** (2006) Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA 103:1810-1815.

113. Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L., Cohen J.C., **Hobbs H.H.** (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78:410-422.
114. Cohen J.C., Boerwinkle E., Mosley T.H., **Hobbs H.H.** (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
115. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., Cohen J.C., **Hobbs H.H.** (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79:514-523.
116. Yang C., McDonald J.G., Patel A., Zhang Y., Umetani M., Xu F., Westover E.J., Covey D.F., Mangelsdorf D.J., Cohen J.C., **Hobbs H.H.** (2006) Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J. Biol. Chem. 281:27816-27826.
117. Wang J., Sun F., Zhang D.W., Ma Y., Xu F., Belani J.D., Cohen J.C., **Hobbs H.H.**, Xie X.S. (2006) Sterol transfer by ABCG5 and ABCG8: in vitro assay and reconstitution. J. Biol. Chem. 281:27894-27904.
118. Romeo S., Cohen J.C., **Hobbs H.H.** (2006) No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB J. 20:2181-2182.
119. Jones C., Garuti R., Michaely P., Li W.P., Maeda N., Cohen J.C., Herz J., **Hobbs H.H.** (2007) Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J. Clin. Invest. 117:165-174. *PMCID: PMC1716209*
120. Horton J.D., Cohen J.C., **Hobbs H.H.** (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32:71-77.
121. Romeo S., Pennacchio L.A., Fu Y., Boerwinkle E., Tybjaerg-Hansen A., **Hobbs H.H.**, Cohen J.C. (2007) Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39:513-516.
122. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., Cohen J.C. and **Hobbs H.H.** (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282:18602-18612.
123. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., Hinds D.A., Pennacchio L.A., Tybjaerg-Hansen A., Folsom A.R., Boerwinkle E., **Hobbs H.H.**, Cohen J.C. (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316:1488-1491. *PMCID: PMC271874*
124. Michaely P., Zhao Z., Li W.P., Garuti R., Huang L.J., **Hobbs H.H.**, Cohen J.C. (2007) Identification of VLDL-induced, FDNPVY-independent internalization mechanism for the LDLR. EMBO J. 26:3273-3282. *PMCID: PMC1933400*
125. Wang J., Zhang D.W., Lei Y., Xu F., Cohen J.C., **Hobbs H.H.**, and Xie X.S. (2008) Purification and reconstitution of sterol transfer by native mouse ABCG5 and ABCG8. Biochemistry 47:5194-5204. *PMCID: PMC2707165*
126. Fahmi S., Yang C., Esmail S., **Hobbs H.H.**, and Cohen J.C. (2008) Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 17:2101-2107. *PMCID: PMC2441721*

127. Zhang D.W, Garuti R., Tang W.J., Cohen J.C., **Hobbs H.H.** (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 105:13045-13050. *PMCID: PMC2526098*
128. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., Boerwinkle E., Cohen J.C., **Hobbs H.H.** (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465. *PMCID: PMC2597056*
129. Horton J.D., Cohen J.C., **Hobbs H.H.** (2009) PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50:S172-S177. *PMCID: PMC2674748*
130. Yin W., Romeo S., Chang S., Grishin N.V., **Hobbs H.H.**, Cohen J.C. (2009) Genetic variation in ANGPTL4 provides insights into protein processing and function. J. Biol. Chem. 284:13213-13222. *PMCID: PMC2676053*
131. Lakoski S., Lagace T.A., Cohen J.C., Horton J.D., **Hobbs H.H.** (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94:2537-2543. *PMCID: PMC2708952*
132. Romeo S., Yin W., Kozlitina J., Pennacchio L.A., Boerwinkle E., **Hobbs H.H.**, Cohen J.C. (2009) Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119:70-79. *PMCID: PMC2613476*
133. Lakoski S.G., Xu F., Vega G.L., Grundy S.M., Chandalia M., Lam C., Lowe R.S., Stepanavage M.E., Musliner T.A., Cohen J.C., **Hobbs H.H.** (2010) Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95: 800-809. *PMCID: PMC3079219*
134. He S., McPhaul C., Li J.Z., Garuti R., Kinch L., Grishin N.V., Cohen J.C., **Hobbs H.H.** (2010) A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285:6706-6715. *PMCID: PMC2825465*
135. Huang Y., He S., Li J.Z., Seo Y-K, Osborne T.F., Cohen J.C., **Hobbs H.H.** (2010) A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. USA 107:7892-7897. *PMCID: PMC2867902*
136. Rios J., Stein E., Shendure J., **Hobbs H. H.**, Cohen J.C. (2010) Identification by whole genome resequencing of gene defect responsible for severe hypercholesterolemia, Hum. Mol. Genet. 19:4313-4318. *PMCID: PMC2957323*
137. Browning J.D., Cohen J.C., **Hobbs H.H.** (2010) Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology 52:1189-1192. *PMCID: PMC3135009*
138. Musunuru K., Pirruccello J.P., Do R., Peloso G.M., Guiducci C., Sougnez C., Garimella K.V., Fisher S., Abreu J., Barry A.J., Fennell T., Banks E., Ambrogio L., Cibulskis K., Kernysky A., Gonzalez E., Rudzicz N., Engert J.C., DePristo M.A., Daly M.J., Cohen J.C., **Hobbs H.H.**, Altshuler D., Schonfeld G., Gabriel S.B., Yue P., Kathiresan S. (2010) Exome sequencing identifies ANGPTL3 as a cause of familial combined hypolipidemia. N. Engl. J. Med. 363:2220-2227. *PMCID: PMC3008575*
139. Kozlitina J., Boerwinkle E., Cohen J.C., **Hobbs H.H.** (2011) Dissociation between AP0C3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53:467-474. *PMCID: PMC3057507*

140. Wang J., Grishin N., Kinch L., Cohen J.C., **Hobbs H.H.** and Xie X-S. (2011) Sequences in the nonconsensus nucleotide binding domain of ABCG5/ABCG8 required for sterol transport. *J. Biol. Chem.* 289:7308-7314. *PMCID: PMC3044967*
141. Ramirez R., Cohen J.C., **Hobbs H.H.**, Browning J.D. (2011) Hepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in NPC1L1. *Hepatology* 54:736-737. *PMCID: PMC3492950*
142. Cohen J.C., Horton J.D., **Hobbs H.H.** (2011) Human fatty liver disease: old questions and new insights. *Science* 332:1519-1523. *PMCID: PMC3229276*
143. Huang Y., Cohen J.C., **Hobbs H.H.** (2011) Expression and characterization of a PNPLA3 isoform (I148M) associated with nonalcoholic fatty liver disease. *J. Biol. Chem.* 286:37085-37093. *PMCID: PMC3199456*
144. Rios J., Shastry S., Jasso J., Hauser N., Garg A., Bensadoun A., Cohen J.C., and **Hobbs H.H.** (2011) Deletion of GPIHBP1 causing severe chylomicronemia. *J. Inherit. Metab. Dis.*, 35:531-540. *PMCID: PMC3319888*
145. Molho-Pessach V., Rios J.J., Xing C., Setchell K.D.R., Cohen J.C., **Hobbs H.H.** (2011) Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology. *Hepatology* 55:1139-1145. *PMCID: PMC3771532*
146. Li Y., Xing C., Cohen J.C., **Hobbs H.H.** (2012) Genetic variant in PNPLA3 associated with nonalcoholic fatty liver disease in China. *Hepatology* 55:327-328. *PMCID: PMC3245325*
147. Wang Y., Huang Y., **Hobbs H.H.**, Cohen J.C. (2012) Molecular characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9)-mediated degradation of the LDLR. *J. Lipid Res.* 53:1932-1943. *PMID:PMC3413232*
148. Li Z.J., Huang Y., Karaman R., Ivanova P.T., Brown A.H., Roddy T., Castro-Perez J., Cohen J.C., and **Hobbs H.H.** (2012) Chronic overexpression of PNPLA3^{I148M} in mouse liver causes hepatic steatosis. *J. Clin. Invest.*, 122:4130–4144. *PMCID: PMC3484461*
149. Quagliarini F., Wang Y., Kozlitina J., Grishin N.V., Hyde R., Boerwinkle E., Valenzuela, D.M., Murphy A.J., Cohen J.C., and **Hobbs H.H.** (2012) Atypical angiopoietin-like protein that regulates ANGPTL3. *Proc. Natl. Acad. Sci. USA* 109:19751-19756. *PMCID: PMC3511699*
150. Cohen J.C. and **Hobbs H.H.** (2013) Simple genetics for a complex disease. *Science* 340: 2013-2014. *PMCID: PMC3839083*
151. Wang Y., Quagliarini F., Gusarova V., Gromada J., Valenzuela D.M., Cohen J.C., **Hobbs H.H.** (2013) Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. *Proc. Natl. Acad. Sci. USA* 110: 16109-16114. *PMCID: PMC3791734*
152. Kozlitina J., Smagris E., Stender S., Nordestgaard B.G., Zhou H.H., Tybjærg-Hansen A., Vogt T.F., **Hobbs H.H.**, and Cohen J.C. (2014) Exome-wide association study identifies a *TM6SF2* variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat. Genet.*, 46: 352-356. *PMCID: PMC3969786*
153. Smagris E., BasuRay S., Li J., Huang Y., Lai K.-V., Gromada J., Cohen J.C. and **Hobbs H. H.** (2014) *Pnpla3*I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. *Hepatology* 61:108-118. *PMCID: PMC4262735*
154. Cohen J.C., Stender S., **Hobbs H.H.** (2014) *APOC3*, coronary disease, and complexities of Mendelian randomization, *Cell Metab.* 20:387-389. *PMCID: PMC4235518*

155. Gusarova V., Alexa C.A., Na E., Stevis P.E., Xin Y., Bonner-Weir S., Cohen J.C., **Hobbs H.H.**, Murphy A.J., Yancopoulos G.D., and Gromada J. (2014) ANGPTL8/Betatrophin does not control pancreatic beta cell expansion. *Cell* 159: 691-696. *PMCID: PMC4243040*
156. Wang J., Mitsche M.A., Luetjohann D., Cohen J.C., Xie X-S., **Hobbs H.H.** (2014) Relative roles of ABCG5/ABCG8 in liver and intestine. *J. Lipid Res.* 56:319-330. *PMCID: PMC4306686*
157. Wang Y., Gusarova V., Banfi S., Gromada J., Cohen J.C., **Hobbs H.H.** (2015) Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. *J. Lipid Res.* 56:1296-1307. *PMCID: PMC4479334*
158. Gusarova V., Alexa C.A., Wang Y., Rafique A., Kim J.H., Buckler D., Mintah I.J., Shihanian L.M., Cohen J.C., **Hobbs H.H.**, Xin Y., Valenzuela D.M., Murphy A.J., Yancopoulos G.D., Gromada J. (2015) ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. *J. Lipid Res.* 56:1308-1317. *PMCID: PMC4479335*
159. Mitsche M.A., McDonald J.G., **Hobbs H.H.**, Cohen J.C. (2015) Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. *eLife* 4: e07999. *PMCID: PMC4501332*
160. Wang Y., McNutt M., Banfi S., Levin M., Holland W.L., Gusarova V., Gromada J., Cohen J.C., **Hobbs H.H.** (2015) Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. *Proc. Natl. Acad. Sci. USA* 112:11630-11635. *PMCID: PMC4479334*
161. Stender S., Chakrabarti R., Xing C., Gotway G., Cohen J.C., **Hobbs H.H.** (2015) Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency. *Mol. Genet. Metab.* 116:269-274. *PMCID: PMC4733618*
162. Lee J.-Y., Kinch L.N., Borek D.M., Wang J., Wang J., Urbatsch I.L., Xie X.-S., Grishin N.V., Cohen J.C., Otwinowski Z., **Hobbs H.H.**, Rosenbaum D.M. (2016) Crystal structure of the human sterol transporter ABCG5/ABCG8. *Nature: in Press.*

BOOK CHAPTERS

1. Goldstein J.L., **Hobbs H.H.**, Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. eds. *The Metabolic and Molecular Bases of Inherited Disease*. 7th ed. New York: McGraw-Hill; 1995:1981-2030.
2. Mancini F.P., Mooser V., Murata J., Newland D., Hammer R.E., Sanan D.A., **Hobbs H.H.** Metabolism and atherogenicity of apo(a) in transgenic mice. In: Woodford FP, Davignon J, and Sniderman A. eds. *Atherosclerosis X*, Elsevier Science; 1995:884-887.
3. Cohen J.C., Gaw A., Barnes R.I., Landschulz K., **Hobbs H.H.** in Ciba Foundation Symposium No. 197, Chadwick D and Cardew G, eds. *Variation in the Human Genome*. Chichester, UK: John Wiley & Sons, Ltd.; 1996:194-206.
4. Mooser V., Cohen J.C., **Hobbs H.H.** Probing the etiology of elevated plasma levels of Lp(a) in African-Americans. In: Jacotot B, Mathè D, Fruchart JC, eds. *Atherosclerosis XI*. 1998:89-95.
5. Gaw A. and **Hobbs H.H.** Lipoprotein(a). In: Betteridge DJ, Illingworth DR and Shepherd J, eds. *Lipoproteins in Health and Disease*. 1st ed. 1999.

6. Goldstein J.L., **Hobbs H.H.**, Brown M.S. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, and Valle D, eds. *The Metabolic and Molecular Bases of Inherited Disease*. 8th ed. New York: McGraw-Hill; 2001:2863-2901.
7. Rader D.J. and **Hobbs H.H.** Disorders of lipoprotein metabolism. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser LS, Jameson JL, eds. *Harrison's Principles of Internal Medicine*, 16th ed. New York: McGraw-Hill; 2005:2286-2298.
8. Rader D.J. and **Hobbs H.H.** Disorders of lipoprotein metabolism. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, and Loscalzo, eds. *Harrison's Principles of Internal Medicine*, 17th ed. New York: McGraw-Hill; 2006:333-355.
9. Rader D.J. and **Hobbs H.H.** Disorders of lipoprotein metabolism. In: Longo DL, Fauci A, Kasper D and Hauser S, Jameson JL, and Loscalzo, J, eds. *Harrison's Principles of Internal Medicine*. 18th ed. New York: McGraw-Hill; 2011:3145-3162.
10. Rader D.J. and **Hobbs H.H.** Disorders of lipoprotein metabolism. In: Kasper D, Fauci A, Hauser S, Longo DL, Jameson JL, and Loscalzo, J, eds. *Harrison's Principles of Internal Medicine*. 19th ed. New York: McGraw-Hill; 2015: Chapter 421.